- Genezen and Humane Genomics have entered a partnership for process transfer, process development, and cGMP manufacturing of HGI627, an oncolytic therapy targeting hepatoblastoma.
- Humane Genomics will leverage its synthetic RNA virus platform, while Genezen will provide viral vector CDMO and contract manufacturing capabilities.
Genezen, a viral vector contract development and manufacturing organisation, has formed a partnership with Humane Genomics to support the development of HGI627, an investigational therapy targeting paediatric liver cancer. The collaboration covers technology transfer, process development, and cGMP manufacturing of the VSV-based therapy.
Humane Genomics is developing a pipeline of synthetic RNA virus candidates with selective anti-cancer activity. Its platform uses a two-factor selectivity mechanism designed to ensure that the engineered viruses replicate only in targeted cancer cells while sparing healthy tissue. HGI627 is the company’s lead programme.
“Genezen is excited to partner with Humane Genomics on this novel cancer treatment and provide our best-in-class manufacturing expertise to bring this critical therapy to life for pediatric patients.”
Steve Favaloro, chairman and chief executive officer of Genezen
Peter Weijmarshausen, co-founder and chief executive officer of Humane Genomics, said the partnership will help translate the company’s science into therapies for patients, citing Genezen’s experienced team and facilities.
The partnership combines Genezen’s viral vector contract manufacturing capability with Humane Genomics’ synthetic RNA virus technology to support the advancement of HGI627 into future stages of development.
